泊沙康唑负载白细胞作为靶向侵袭性肺曲霉病的新型治疗策略
本研究探讨体外负载泊沙康唑的白细胞能否改善抗真菌药物向感染部位的递送。分化的HL-60细胞(dHL-60)负载泊沙康唑后,胞内药物浓度达暴露浓度的265倍,保持活力和趋化能力,并在体外接触依赖性地将药物转移至菌丝、降低真菌活力。在中性粒细胞减少小鼠IPA模型中,负载泊沙康唑的dHL-60细胞较单用dHL-60细胞显著降低真菌负荷。
要点
- dHL-60细胞可高浓度富集泊沙康唑,胞内水平为暴露浓度的265倍
- 负载细胞保持活力和趋化功能,体外可将泊沙康唑转移至菌丝并降低真菌活力
- 中性粒细胞减少IPA小鼠中,负载泊沙康唑的dHL-60细胞较单用dHL-60细胞显著降低真菌负荷
核心结论
- 泊沙康唑在dHL-60细胞中高浓度蓄积,并增强其体外和体内抗真菌活性,提示负载泊沙康唑的白细胞可能成为IPA的治疗策略。
研究设计与样本
- 体外研究使用分化的HL-60(dHL-60)细胞,暴露于不同浓度泊沙康唑,评估功能与抗真菌活性。
- 体内研究采用中性粒细胞减少小鼠IPA模型,比较负载泊沙康唑的dHL-60细胞与单用dHL-60细胞的疗效。
主要发现
- dHL-60细胞内泊沙康唑水平为暴露浓度的265倍。
- 负载泊沙康唑的细胞保持活力并可进行主动趋化。
- 体外观察到dHL-60细胞接触依赖性转移泊沙康唑至菌丝,导致真菌活力下降。
- 中性粒细胞减少IPA小鼠中,负载泊沙康唑的dHL-60细胞较单用dHL-60细胞显著降低真菌负荷。
临床怎么用
- 目前仅为实验性研究,尚未提供临床用药方案或剂量推荐。
- 该策略可能为侵袭性肺曲霉病提供新的药物递送思路,但需进一步临床前和临床验证。
局限性
- 研究使用HL-60细胞系分化的中性粒细胞样细胞,非原代人类中性粒细胞。
- 证据来自体外实验和小鼠模型,尚未在人体中验证。
- 未报告临床结局、药代动力学参数或安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Impaired delivery of antifungals to hyphae within necrotic lesions is thought to contribute to therapeutic failure in invasive pulmonary aspergillosis (IPA). We hypothesized that transfusion of leukocytes loaded ex vivo with the lipophilic antifungal posaconazole could improve delivery of antifungals to the sites of established infection and improve outcome in experimental IPA. METHODS: The HL-60 leukemia cell line was differentiated to a neutrophil-like phenotype (differentiated HL-60 [dHL-60] cells) and then exposed to a range of posaconazole concentrations. The functional capacity and antifungal activity of these cells were assessed in vitro and in a mouse model of IPA. RESULTS: Posaconazole levels in dHL-60 cells were 265-fold greater than the exposure concentration. Posaconazole-loaded cells were viable and maintained their capacity to undergo active chemotaxis. Contact-dependent transfer of posaconazole from dHL-60 cells to hyphae was observed in vitro, resulting in decreased fungal viability. In a neutropenic mouse model of IPA, treatment with posaconazole-loaded dHL-60 cells resulted in significantly reduced fungal burden in comparison to treatment with dHL-60 cells alone. CONCLUSIONS: Posaconazole accumulates at high concentrations in dHL-60 cells and increases their antifungal activity in vitro and in vivo. These findings suggest that posaconazole-loading of leukocytes may hold promise for the therapy of IPA.
引用
- Baistrocchi SR, Lee MJ, Lehoux M, et al. Posaconazole-Loaded Leukocytes as a Novel Treatment Strategy Targeting Invasive Pulmonary Aspergillosis. J Infect Dis. 2017. PMID: 27799353. doi:10.1093/infdis/jiw513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。